Key result
De-escalation from ticagrelor to clopidogrel reduced 1-year net adverse clinical events in patients <75y without age interaction.
Why the study?
The clinical effects of dual antiplatelet therapy de-escalation from ticagrelor to clopidogrel in stabilized patients after acute myocardial infarction and PCI may differ by age.
Does de-escalation from ticagrelor to clopidogrel 1 month after PCI reduce the composite of major adverse cardiovascular events and BARC types 2, 3, or 5 bleeding across different age groups (<75 vs ≥75 years) in stabilized patients with acute myocardial infarction?
RCT (n=2,697)
Randomized
Does de-escalation from ticagrelor to clopidogrel 1 month after PCI reduce the composite of major adverse cardiovascular events and BARC types 2, 3, or 5 bleeding across different age groups (<75 vs ≥75 years) in stabilized patients with acute myocardial infarction?
In stabilized post-PCI patients with acute myocardial infarction, de-escalating from ticagrelor to clopidogrel after 1 month significantly reduces net clinical events and bleeding in patients under 75 years without significant age-treatment interaction, though certainty in patients ≥75 years remains limited.
Answers are grounded in this paper and cite their sources.
Age-specific DAPT de-escalation effects after AMI remain uncertain; leaves open tailored strategies pending dedicated trials.
The clinical effects of dual antiplatelet therapy de-escalation after acute myocardial infarction may differ by age. We evaluated whether the efficacy and safety of de-escalation from ticagrelor to clopidogrel differed by age in stabilized patients after percutaneous coronary intervention (PCI). This was a prespecified secondary analysis of the TALOS-AMI randomized trial. Patients event-free 1 month after PCI receiving aspirin–ticagrelor were randomly allocated to de-escalation (aspirin–clopidogrel) or continuation (aspirin–ticagrelor). The primary net clinical endpoint was a composite of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke) and Bleeding Academic Research Consortium types 2, 3, or 5 bleeding at 1 year. We included 2697 participants (mean age 60.0 ± 11.4 years; 16.8% women). Among patients aged <75 years (n = 2376), de-escalation reduced the primary net clinical endpoint (4.1% vs. 7.2%; adjusted hazard ratio (aHR), 0.54 [95% CI, 0.38–0.77]) and bleeding (2.8% vs. 4.9%; aHR, 0.54 [0.35–0.82]). Among patients aged ≥75 years, no significant differences were observed for the primary endpoint (6.4% vs. 11.6%; aHR0.54 [0.25–1.17]) or bleeding (3.2% vs. 7.9%; aHR, 0.41 [0.15–1.15]). Interaction testing showed no treatment effect modification by age for the primary endpoint (p for interaction = 0.978), MACE (p = 0.585), or BARC bleeding (p = 0.597). Among patients aged ≥75 years, 14/18 bleeding events occurred within 180 days. Among stabilized, event-free patients 1 month after PCI, no significant age–treatment interaction was observed; therefore, the efficacy and safety of de-escalation in older adults (≥75 years) remain uncertain. Trial registration: ClinicalTrials.gov (NCT02018055). In this prespecified secondary analysis of the TALOS-AMI trial, clopidogrel-based de-escalation was associated with lower risks of the primary net clinical endpoint and BARC type 2, 3, or 5 bleeding among patients aged <75 years, while MACE did not differ significantly between treatment strategies. Among patients aged ≥75 years, no statistically significant between-group differences were observed for the primary net clinical endpoint, MACE, or BARC type 2, 3, or 5 bleeding. No statistically significant treatment-by-age interaction was detected using the prespecified 75 years cutoff, alternative 65 and 70 years cutoffs, or age as a continuous variable; the efficacy and safety of de-escalation specifically in older adults remain uncertain.
No takes yet. Share an insight, caveat, or question.
Bu et al. (2026) conducted an RCT in Acute myocardial infarction post-PCI (n=2,697). De-escalation to aspirin-clopidogrel vs. Continuation of aspirin-ticagrelor was evaluated on Composite of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke) and BARC types 2, 3, or 5 bleeding at 1 year (aHR 0.54, 95% CI 0.38-0.77, p=0.978 for interaction). De-escalation from ticagrelor to clopidogrel reduced 1-year net adverse clinical events in patients <75y without age interaction.
Synapse has enriched 10 related papers. Consider them for comparative context: